Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DOLUTEGRAVIR & RILPIVIRINE

All products: general benefit

Other products in the same Health Canada class (J05AR) — coverage varies; not interchangeable

  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit
  • Abacavir + lamivudine (Kivexa): general benefit
  • Bictegravir + emtricitabine + tenofovir alafenamide hemifumarate (Biktarvy): general benefit
  • Cabotegravir + rilpivirine (Cabenuva): general benefit
  • Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil (Stribild): general benefit
  • Cobicistat + darunavir (Prezcobix): general benefit

48 more in the class list below

Juluca · DIN 02475774 · 50mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

ViiV Supports Patient Support Program

Manufacturer assistance may reduce out-of-pocket costs. If this ViiV medication is prescribed and cost is a barrier, ask your pharmacist about ViiV Supports. Canadian residence and a valid prescription are required; the program assesses financial need.

1-855-525-5300 · Canadian ViiV support and registration

Manufacturer assistance is not subtracted from public estimates. Final out-of-pocket cost is not established.

Assistance conditions and dated sources

The amount, maximum, duration and detailed financial eligibility have not been confirmed. Assistance is not guaranteed.

A Trillium deductible interaction is not stated in the public materials checked. Ask ViiV Supports and the pharmacist to confirm. No assistance is subtracted from public estimates.

Ask your pharmacist about ViiV Supports, or call the Canadian program before registering. It can help check public and private coverage options.

A valid prescription for a participating ViiV product is required. A product match does not establish the reason it was prescribed or financial eligibility.

The current welcome page states Monday to Friday, 8 am to 8 pm EST; confirm availability with the program.

Possible temporary financial assistance at the manufacturer's discretion; eligibility is not guaranteed and support may change or end.

“The program offers reimbursement navigation services to assist patients in obtaining public and/or private coverage.” June 2026, code PM-CA-HVX-WCNT-260001; accessed 2026-09-18

“Your eligibility in the Program is not guaranteed” Undated current linked terms, pages 1-2; accessed 2026-09-18

No interchangeable product listed in the Ontario extract
Juluca · DIN 02475774 Manufacturer: ViiV Healthcare ULC; listing date 2019-04-30 Health Canada: Marketed since 2018-06-04 · brand JULUCA · ATC J05AR21 DOLUTEGRAVIR AND RILPIVIRINE, J05AR21 DOLUTEGRAVIR AND RILPIVIRINE · form Tablet · route Oral · ingredients DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MG, RILPIVIRINE (RILPIVIRINE HYDROCHLORIDE) 25 MG · company Viiv healthcare ulc · schedule Prescription
Check this DIN again · Health Canada product record

Juluca: Formulary list price $41.7120/unit (unit not stated in source; not the patient's cost)

Ministry pays: $41.7120 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96645 · Verify on the e-Formulary ↗ (DIN 02475774)

Source record
DIN 02475774: Juluca Raw flags: sec3=Y Item: 081800392; group id 75; item number 0143; lccId None; manufacturer id VIH Source form: Tab; strength: 50mg & 25mg Recorded listing: General benefit Source prices (unrounded): $41.7120; ministry $41.7120 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02475774 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96645
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02475774
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (08:18 Antivirals) and how they are covered

Matched class: 08:18 Antivirals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABACAVIR & LAMIVUDINE & ZIDOVUDINE, ABACAVIR SULFATE, ABACAVIR SULFATE & LAMIVUDINE, BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE, CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, DARUNAVIR & COBICISTAT, DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, DELAVIRDINE MESYLATE, DOLUTEGRAVIR, DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE, DOLUTEGRAVIR SODIUM/LAMIVUDINE, DORAVIRINE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR ALAFENAMIDE HEMIFUMARATE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, ETRAVIRINE, FOSAMPRENAVIR CALCIUM, GANCICLOVIR SODIUM, LAMIVUDINE & ZIDOVUDINE, LOPINAVIR & RITONAVIR, MARAVIROC, NELFINAVIR MESYLATE, RALTEGRAVIR POTASSIUM, RILPIVIRINE HYDROCHLORIDE, RITONAVIR Some products covered without a code (check the product listing): ACYCLOVIR, ATAZANAVIR SULFATE, DARUNAVIR, EFAVIRENZ, LAMIVUDINE, NEVIRAPINE, VALACYCLOVIR 08:18 Antivirals

ABACAVIR & LAMIVUDINE & ZIDOVUDINE

· 2 products · General benefit · strengths: 300mg & 150mg & 300mg · Tab

ABACAVIR SULFATE & LAMIVUDINE

· 7 products · General benefit · strengths: 600mg & 300mg · Tab

BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE

· 1 products · General benefit · strengths: 50mg & 200mg & 25mg · Tab

CABOTEGRAVIR & RILPIVIRINE

· 2 products · General benefit · strengths: 200mg/mL & 300mg/mL · Inj Sol-2mL Kit, Inj Sol-3mL Kit

COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE

· 1 products · General benefit · strengths: 150mg & 150mg & 200mg & 300mg · Tab

DARUNAVIR & COBICISTAT

· 1 products · General benefit · strengths: 800mg & 150mg · Tab

DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE

· 1 products · General benefit · strengths: 800mg & 150mg & 200mg & 10mg · Tab

DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE

· 1 products · General benefit · strengths: 50mg & 600mg & 300mg · Tab

DOLUTEGRAVIR SODIUM/LAMIVUDINE

· 1 products · General benefit · strengths: 50mg & 300mg · Tab

DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE

· 1 products · General benefit · strengths: 100mg & 300mg & 300mg · Tab

EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE

· 7 products · General benefit · strengths: 600mg/300mg/200mg · Tab

ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE

· 1 products · General benefit · strengths: 150mg & 150mg & 200mg & 10mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:18 and 42 more
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 Indications JULUCA (dolutegravir/rilpivirine) is indicated as a complete regimen to replace the current antiretroviral regimen for: • the treatment of human immunodeficiency virus (HIV-1) infection in adults who are virologically stable and suppressed (HIV-1 RNA less than 50 copies per mL). 1.1 Pediatrics Pediatrics (< 18 years of age): Safety and efficacy of JULUCA have not been established in pediatric patients less than 18 years of age. 1.2 Geriatrics Geriatrics (≥ 65 years of age): Clinical studies of JULUCA did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from adult patients < 65 years of age. https://pdf.hres.ca/dpd_pm/00082175.PDF PM date: 2025-10-24 Source product: JULUCA; DIN 02475774; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.